Abstract 76 Table 1
| Endpoints | DSA in the first year post-HTx (n=69) | No DSA in the first-year post-HTx (n=223) | No DSA in the first-year post-HTx (n=223) |
|---|---|---|---|
| 1 Year Survival | 89.9% | 89.2% | 0.796 |
| 1 Year Freedom from Any-Treated Rejection | 75.4% | 90.1% | 0.002 |
| 1 Year Freedom from Acute Cellular Rejection | 85.5% | 95.1% | 0.011 |
| 1 Year Freedom from Antibody-Mediated Rejection | 89.9% | 98.7% | 0.001 |
| 1 Year Freedom from Biopsy-Negative Rejection | 89.9% | 96.0% | 0.068 |
| 3 Year Freedom from CAV | 76.8% | 74.0% | 0.618 |
| 5 Year Freedom from CAV | 72.5% | 65.5% | 0.293 |
| 3 Year Freedom from NF-MACE | 85.5% | 87.4% | 0.753 |
| 5 Year Freedom from NF-MACE | 85.5% | 86.0% | 0.956 |
| NF-MACE: myocardial infarction, new heart failure, coronary intervention, implantable cardioverter defibrillator/pacemaker implant, stroke | |||
| Endpoints | Persistent DSA (n= 14) | Transient DSA (n= 55) | P-value |
| 3 Year Freedom from CAV | 57.1% | 75.0% | 0.192 |
| 5 Year Freedom from CAV | 50.0% | 68.7% | 0.175 |